Unprecedented developments in cannabinoid research within the past decade include discovery of a brain (CB 1 ) and peripheral (CB 2 ) receptor; endogenous ligands, anandamide, and 2-arachidonylglycerol; cannabinoid drug-induced partial and inverse agonism at CB 1 receptors, antagonism of NMDA receptors and glutamate, and antioxidant activity; and preferential CB 1 receptor localization in areas subserving spasticity, pain, abnormal involuntary movements, seizures, and amnesia. These endogenous structures and chemicals and mechanisms are potentially new pathophysiologic substrates, and targets for novel cannabinoid treatments, of several neurological disorders. 1998 Academic Press
INTRODUCTION
The use of marijuana (cannabis) for medical purposes has a long history (1,2). It spans from folkloric use in ancient times, through physician prescription in the 19th century, to illegal self-medication in the present time. Modern research into the purported therapeutic effects of marijuana began with the identification in the 1960s of ⌬ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD) as the major psychoactive and nonspychoactive cannabinoids of marijuana, respectively (3). However, it is only within the past 10 years that pivotal information has emerged on the newly discovered cannabinoid receptors, endogenous ligands, and drugs. Some selected reviews on these topics are the neuropharmacology of cannabinoids (4), the anatomy of cannabinoid receptors (5), cannabinoid receptor biochemistry, physiology, and pharmacology (6-11), the molecular biology of cannabinoid receptors (12,13), the pharmacology of anandamide and other eicosanoids (14-16), basal ganglia effects of cannabinoids (17), and effects of cannabinoids and marijuana in neurological disorders (18, 19) .
The purpose of this report is to review selective information from preclinical and clinical reports to provide, if possible, some hypotheses of how cannabinoid receptors, or other endogenous cannabinoid systems, might be targets for therapy of neurological disorders. These disorders are listed in Table 1 . Specific information of marijuana and/or cannabinoid effects on each of these potential therapeutic indications is presented in the following sections.
CENTRAL DISTRIBUTION OF CANNABINOID RECEPTORS AND ENDOGENOUS LIGANDS
The brain and spinal cord have cannabinoid receptors, termed CB 1 (20) . A second type of cannabinoid receptor, termed CB 2 (21), is located in the periphery (11). The brain also contains anandamide, 2-arachidonoylglycerol, and other endogenous ligands of the eicosanoid class (22-25). The highest densities of CB 1 receptors in humans (and most other species as well) are in the substantia nigra pars reticulata (SNr), globus pallidus (GP), hippocampus, and cerebellum; high to moderate densities are present in the cerebral cortex and striatum (caudate nucleus and putamen); sparse densities exist in most parts of the brain stem and in the spinal cord (26, 27) . The SNr and GP are the major output nuclei of the basal ganglia, and in these structures CB 1 receptors are located predominately presynaptically on striatonigral and striatopallidal neurons (17). A more recent study in adult human brain has provided the most detailed and quantitative data of CB 1 receptors in all major regions of the brain and spinal cord (28). Of several notable findings, one concerned the cerebral cortex. CB 1 receptors were more dense in secondary sensory and secondary motor
